Research
Hormonal
Tirzepatide is in phase 3 development for adults with obesity or overweight with weight-related comorbidity.
Practitioners should be aware of Tirzepatide's potential for treating obesity in clinical settings.
StrongSupportsmedium confidence
Tirzepatide is in phase 3 development for adults with obesity or overweight with weight-related comorbidity.
Why this rating
The claim is based on the status of clinical trials, which is a reliable form of evidence.
Source
Tirzepatide: Revolutionary Drug in Management of “Diabesity”
Vansh Chouhan et al. · International Journal of Medical and Dental Sciences · 2022
other
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →